New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:15 EDTHPTXHyperion Therapeutics announces RAVICTI NDS accepted by Health Canada
Hyperion Therapeutics announced that the validation period is complete for its New Drug Submission to Health Canada for RAVICTI Oral Liquid for the treatment of urea cycle disorders, and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months. The NDS is based on results from 10 controlled and uncontrolled clinical trials studying the safety and efficacy of RAVICTI in 359 patients across three populations, including 114 UCD patients. Data from multiple Canadian patients enrolled at the University of Toronto were included in the submission. The safety and efficacy of RAVICTI is under review by Health Canada and market authorization has not yet been granted.
News For HPTX From The Last 14 Days
Check below for free stories on HPTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
07:54 EDTHPTXHyperion Therapeutics price target lowered to $38 from $43 at Cantor
Subscribe for More Information
September 9, 2014
09:08 EDTHPTXHyperion Therapeutics weakness creates buying opportunity, says JMP Securities
Subscribe for More Information
September 8, 2014
12:18 EDTHPTXOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTHPTXHyperion Therapeutics program end removes catalyst, says Leerink
Leerink says Hyperion Therapeutics' termination of its DiaPep277 program removes a near-term catalyst and potential upside driver. The firm reiterates an Outperform rating on the stock, however, noting the Ravicti base business remains strong.
10:40 EDTHPTXHyperion Therapeutics drops on termination of DiaPep277 program
Subscribe for More Information
09:12 EDTHPTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTHPTXHyperion terminates DiaPep277 program, finds misconduct by Andromeda Biotech
Subscribe for More Information
08:01 EDTHPTXHyperion terminates DiaPep277 program, finds misconduct by Andromeda Biotech
Subscribe for More Information
07:51 EDTHPTXHyperion Therapeutics trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use